These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30735525)

  • 1. Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice.
    Choung S; Kim JM; Joung KH; Lee ES; Kim HJ; Ku BJ
    PLoS One; 2019; 14(2):e0210828. PubMed ID: 30735525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.
    Liang D; Chen H; Zhao L; Zhang W; Hu J; Liu Z; Zhong P; Wang W; Wang J; Liang G
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):133-142. PubMed ID: 29038049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic Inhibition of Epidermal Growth Factor Receptor Suppresses Nonalcoholic Fatty Liver Disease in a Murine Fast-Food Diet Model.
    Bhushan B; Banerjee S; Paranjpe S; Koral K; Mars WM; Stoops JW; Orr A; Bowen WC; Locker J; Michalopoulos GK
    Hepatology; 2019 Nov; 70(5):1546-1563. PubMed ID: 31063640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR.
    Song J; Liu Y; Wan J; Zhao GN; Wang JC; Dai Z; Hu S; Yang L; Liu Z; Fu Y; Dong E; Tang YD
    Hepatology; 2021 Dec; 74(6):3091-3109. PubMed ID: 34320238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice.
    Veiga FMS; Graus-Nunes F; Rachid TL; Barreto AB; Mandarim-de-Lacerda CA; Souza-Mello V
    Biochimie; 2017 Sep; 140():106-116. PubMed ID: 28711683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
    Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
    J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-17A exacerbates high-fat diet-induced hepatic steatosis by inhibiting fatty acid β-oxidation.
    Shen T; Chen X; Li Y; Tang X; Jiang X; Yu C; Zheng Y; Guo H; Ling W
    Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1510-1518. PubMed ID: 28153707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.
    Prada PO; Ropelle ER; Mourão RH; de Souza CT; Pauli JR; Cintra DE; Schenka A; Rocco SA; Rittner R; Franchini KG; Vassallo J; Velloso LA; Carvalheira JB; Saad MJ
    Diabetes; 2009 Dec; 58(12):2910-9. PubMed ID: 19696185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
    Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
    Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1.
    Meng X; Guo J; Fang W; Dou L; Li M; Huang X; Zhou S; Man Y; Tang W; Yu L; Li J
    J Biol Chem; 2016 May; 291(20):10625-34. PubMed ID: 27013659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway.
    Xu N; Luo H; Li M; Wu J; Wu X; Chen L; Gan Y; Guan F; Li M; Su Z; Chen J; Liu Y
    Biomed Pharmacother; 2021 Feb; 134():111104. PubMed ID: 33341045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.
    Huang H; Lee SH; Sousa-Lima I; Kim SS; Hwang WM; Dagon Y; Yang WM; Cho S; Kang MC; Seo JA; Shibata M; Cho H; Belew GD; Bhin J; Desai BN; Ryu MJ; Shong M; Li P; Meng H; Chung BH; Hwang D; Kim MS; Park KS; Macedo MP; White M; Jones J; Kim YB
    J Clin Invest; 2018 Dec; 128(12):5335-5350. PubMed ID: 30226474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
    Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
    Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
    Luo Y; Yang P; Li Z; Luo Y; Shen J; Li R; Zheng H; Liang Y; Xia N
    Drug Des Devel Ther; 2019; 13():4065-4074. PubMed ID: 31819375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway.
    Zhang Y; Li C; Li X; Wu C; Zhou H; Lu S; Liu X
    Mol Med Rep; 2020 Sep; 22(3):2174-2182. PubMed ID: 32705195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.